GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophylaxis (PrEP) available in ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Additionally, the company has developed next-generation drugs in respiratory and HIV areas that should help mitigate both branded and generic competition. We expect GSK to be a major competitor in ...

What it means: A reduction to the CDC's HIV budget has implications for drugmakers focused on combating this disease. Aside from Gilead, American depositary shares of GSK fell 2.18% in early trading.

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir ...

Its operations are structured around three core therapeutic areas: infectious diseases, HIV, and immunology/respiratory. GSK is a world leader in vaccines and has a broad portfolio targeting ...

GlaxoSmithKline Pharmaceuticals is a subsidiary of the GSK Group in India. Its objective is to get ahead of disease with the ...